Synchron Raises $200 Million to Advance Brain-Computer Interface for Paralysis
Synchron has secured $200 million in a Series D funding round to expand its operations and speed up the commercialization of its non-surgical brain-computer interface (BCI) designed for people with paralysis. This latest investment increases the company’s total funding to $345 million.
Funding Details and Investors
The Series D round was led by Double Point Ventures and included participation from existing investors such as Arch Ventures, Khosta Ventures, Bezos Expeditions, NTI, and Metis. Additional new investors include the Australian National Reconstruction Fund, T.Rx Capital, the Qatar Investment Authority, K5 Global, Protocol Labs, and IQT.
Growing Momentum in Brain-Computer Interface Technology
The investment reflects the increasing interest and progress in BCI technologies. Earlier, Precision Neuroscience announced a partnership with SCI Ventures, backed by the Christopher & Dana Reeve Foundation, to develop its Layer 7 Cortical Interface. Additionally, Science Corp. demonstrated promising results with its PRIMA BCI retinal implant, restoring partial vision to individuals with advanced age-related macular degeneration.
“Synchron will use this funding to expand operations and accelerate commercialization of its non-surgical brain-computer interface for people with paralysis.”
These developments highlight the advancing potential of BCIs to improve the quality of life for those with neurological impairments.
Author’s Summary
Synchron’s $200 million funding boost will accelerate its non-surgical brain-computer interface, reflecting growing momentum in technologies aimed at restoring function for people with paralysis.